Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
04 Januar 2021 - 12:37PM
Edgar (US Regulatory)
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of January 2021
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Atacand divestment to Cheplapharm in more than 70 countries
completed
4 January 2021 07:00 GMT
Atacand divestment to Cheplapharm in more than 70
countries completed
AstraZeneca has completed the divestment of commercial rights
to Atacand (candesartan
cilexetil) and Atacand Plus (a fixed-dose
combination of candesartan cilexetil and
hydrochlorothiazide) in
over 70 countries to Cheplapharm Arzneimittel
GmbH (Cheplapharm).
Financial considerations
Under the terms of the agreement AstraZeneca received a payment of
$250m from Cheplapharm. AstraZeneca will receive further
non-contingent payments equal to $150m during the first half of
2021. The present value of all payments, totalling $400m, will be
reported in AstraZeneca's financial statements within Other
Operating Income in the fourth quarter of 2020.
Pursuant to London Stock Exchange listing rule 10.4.1R
(notification of class 2 transactions), in 2019 Atacand and Atacand Plus generated product sales of $148m and profit
before tax of $89m in the countries covered by the
agreement. The gross book value of
assets subject to the divestment at 31 December 2019
was $nil. The
consideration was and will be paid in cash, and the proceeds used
for general corporate purposes.
Atacand
Atacand (candesartan
cilexetil) is a selective AT1 subtype angiotensin II receptor
antagonist that is indicated for the management of hypertension in
adults and children/adolescents, as well as heart failure in
adults. Atacand
Plus is indicated for the
management of hypertension when candesartan or hydrochlorothiazide
monotherapy is not sufficiently effective. Atacand was developed in collaboration with Takeda
Pharmaceutical Company Limited. Each company held the exclusive
rights to the medicine in certain countries; in other
countries, Atacand was co-marketed.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global,
science-led biopharmaceutical company that focuses on the
discovery, development and commercialisation of prescription
medicines, primarily for the treatment of diseases in three therapy
areas - Oncology, Cardiovascular, Renal & Metabolism, and
Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca
operates in over 100 countries and its innovative medicines are
used by millions of patients worldwide. Please
visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
04 January
2021
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024